2024-03-29T06:55:53Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00021283
2022-12-15T03:51:51Z
453:456
471:537:538:1182
Recent Advances in DIC for Ten Years
5) DIC : この十年間の歩み(新潟血栓止血研究会10周年記念特別例会記録)
5) DIC : この十年間の歩み(新潟血栓止血研究会10周年記念特別例会記録)
佐藤, 正之
130315
村川, 英三
130316
Disseminated intravascular coagulation (DIC)
Molecular markers for coagulatin and fibrinolysis
Acute promyelocytic leukemia
therapy of DIC
血管内凝固症候群
分子マーカー
急性前骨髄球性白血病
治療
To diagnose DIC, we have always been looking for new parameters: e.g. fibrinogen and fibrin degradation products (FDP), antithrombinIII (ATIII), α_2 plasmin inhibitor (α_2PI), fibrinmonomer complex (FM) and D dimer (D-D). But these parameters have many problems: FDP can not distinguish between primary fibrinolysis and secondary fibrinolysis. With low plasma levels of ATIII and α_2PI, we can not see they are due to comsumption or due to reduced production. FM is not quantitative analysis. D-D which is specific for secondary fibrinolygis, is too sensitive to assess secondary fibrinolysis in DIC. We evaluated new molecular markers for the diagnosis of DIC in acute promyelocytic leukemia and other disorders: Thrombin antithrombin III complex (TAT) and plasmin・α_2 plasmin inhibitor complex (PIC). TAT and PIC were extremely elevated even though in probable DIC group with DIC scor<4. Abnormal findings of these parameters in probable DIC group seem to show hypercoagulability and fibrinolysis in this group. So plasma levels of TAT and PIC for the diagnosis of DIC should be established. With our data, plasma levels of both TAT≧7.5μg/l and PIC≧2.5μg/ml, three times of normal value, are valuable for the diagnosis of DIC. Recently the therapy of DIC has greatly advanced using synthetic protease inhibitors and ATIII concentrate.
departmental bulletin paper
新潟医学会
1991-09
application/pdf
新潟医学会雑誌
9
105
632
638
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/21283/files/105(9)_632-638.pdf
jpn